Mobile telephone delivered contingency management for encouraging adherence to supervised methadone consumption: feasibility study for an RCT of clinical and cost-effectiveness (TIES).

Contingency management Medication adherence Mobile telephone Opioid agonist treatment

Journal

Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536

Informations de publication

Date de publication:
07 Jan 2021
Historique:
received: 11 08 2020
accepted: 18 12 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 8 1 2021
Statut: epublish

Résumé

Prescription methadone or buprenorphine enables people with opioid use disorder to stop heroin use safely while avoiding withdrawal. To ensure methadone is taken as prescribed and to prevent diversion onto the illicit market, people starting methadone take their daily dose under a pharmacist's supervision. Many patients miss their daily methadone dose risking withdrawal, craving for heroin and overdose due to loss of heroin tolerance. Contingency management (CM) can improve medication adherence, but remote delivery using technology may be resource-light and cost-effective. We developed an innovative way to deliver CM by mobile telephone. Software monitors patients' attendance and supervised methadone consumption through an internet self-login at the pharmacy and sends reinforcing text messages to patients' mobile telephones. A linked system sends medication adherence reports to prescribers and provides early warning alerts of missed doses. A pre-paid debit card system provides financial incentives. A cluster randomised controlled trial design was used to test the feasibility of conducting a future trial of mobile telephone CM to encourage adherence to supervised methadone in community pharmacies. Each cluster (drug service/3 allied pharmacies) was randomly allocated to provide patient's presenting for a new episode of opiate agonist treatment (OAT) with either (a) mobile telephone text message CM, (b) mobile telephone text message reminders, or (c) no text messages. We assessed acceptability of the interventions, recruitment, and follow-up procedures. Four drug clinics were approached and three recruited. Thirty-three pharmacists were approached and 9 recruited. Over 3 months, 173 individuals were screened and 10 enrolled. Few patients presented for OAT and high numbers were excluded due to receiving buprenorphine or not attending participating pharmacies. There was 96% consistency in recording medication adherence by self-login vs. pharmacy records. In focus groups, CM participants were positive about using self-login, the text messages, and debit card. Prescribers found weekly reporting, time saving, and allowed closer monitoring of patients. Pharmacists reported that the tablet device was easy to host. Mobile telephone CM worked well, but a planned future trial will use modified eligibility criteria (existing OAT patients who regularly miss their methadone/buprenorphine doses) and increase the number of participating pharmacies. The trial is retrospectively registered, ISRCTN 58958179 .

Sections du résumé

BACKGROUND BACKGROUND
Prescription methadone or buprenorphine enables people with opioid use disorder to stop heroin use safely while avoiding withdrawal. To ensure methadone is taken as prescribed and to prevent diversion onto the illicit market, people starting methadone take their daily dose under a pharmacist's supervision. Many patients miss their daily methadone dose risking withdrawal, craving for heroin and overdose due to loss of heroin tolerance. Contingency management (CM) can improve medication adherence, but remote delivery using technology may be resource-light and cost-effective. We developed an innovative way to deliver CM by mobile telephone. Software monitors patients' attendance and supervised methadone consumption through an internet self-login at the pharmacy and sends reinforcing text messages to patients' mobile telephones. A linked system sends medication adherence reports to prescribers and provides early warning alerts of missed doses. A pre-paid debit card system provides financial incentives.
METHODS METHODS
A cluster randomised controlled trial design was used to test the feasibility of conducting a future trial of mobile telephone CM to encourage adherence to supervised methadone in community pharmacies. Each cluster (drug service/3 allied pharmacies) was randomly allocated to provide patient's presenting for a new episode of opiate agonist treatment (OAT) with either (a) mobile telephone text message CM, (b) mobile telephone text message reminders, or (c) no text messages. We assessed acceptability of the interventions, recruitment, and follow-up procedures.
RESULTS RESULTS
Four drug clinics were approached and three recruited. Thirty-three pharmacists were approached and 9 recruited. Over 3 months, 173 individuals were screened and 10 enrolled. Few patients presented for OAT and high numbers were excluded due to receiving buprenorphine or not attending participating pharmacies. There was 96% consistency in recording medication adherence by self-login vs. pharmacy records. In focus groups, CM participants were positive about using self-login, the text messages, and debit card. Prescribers found weekly reporting, time saving, and allowed closer monitoring of patients. Pharmacists reported that the tablet device was easy to host.
CONCLUSION CONCLUSIONS
Mobile telephone CM worked well, but a planned future trial will use modified eligibility criteria (existing OAT patients who regularly miss their methadone/buprenorphine doses) and increase the number of participating pharmacies.
TRIAL REGISTRATION BACKGROUND
The trial is retrospectively registered, ISRCTN 58958179 .

Identifiants

pubmed: 33407950
doi: 10.1186/s40814-020-00761-4
pii: 10.1186/s40814-020-00761-4
pmc: PMC7789356
doi:

Types de publication

Journal Article

Langues

eng

Pagination

14

Subventions

Organisme : National Institute for Health Research
ID : PB-PG-0815-20053

Références

Drug Alcohol Depend. 2020 Oct 1;215:108201
pubmed: 32777691
Addiction. 2006 Nov;101(11):1546-60
pubmed: 17034434
Addiction. 2006 Feb;101(2):192-203
pubmed: 16445548
Prev Med. 2016 Nov;92:36-46
pubmed: 27514250
Prev Med. 2012 Nov;55 Suppl:S86-94
pubmed: 22580095
Br J Psychiatry. 2013 Nov;203(5):341-9
pubmed: 24029536
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Br J Addict. 1992 May;87(5):733-42
pubmed: 1591524
Addiction. 2019 Nov;114(11):1915-1925
pubmed: 31265747
Br J Addict. 1991 Oct;86(10):1311-6
pubmed: 1751846
Addiction. 2015 Jun;110(6):891-8
pubmed: 25490943
Contemp Clin Trials Commun. 2019 Dec 10;17:100506
pubmed: 31909291
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
AIDS Behav. 2015 Jun;19 Suppl 2:156-62
pubmed: 25645326
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Occup Environ Med. 2003 Feb;45(2):156-74
pubmed: 12625231
Addiction. 2007 Nov;102(11):1824-30
pubmed: 17935587

Auteurs

N Metrebian (N)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK. nicola.metrebian@kcl.ac.uk.

E Carr (E)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.

K Goldsmith (K)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.

T Weaver (T)

Department of Mental Health, Social Work and Integrative Medicine, School of Health and Education, Middlesex University, London, NW4 4BT, UK.

S Pilling (S)

Research Department of Clinical Health and Educational Psychology, University College London, London, WC1 7HB, UK.

J Shearer (J)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.

K Woolston-Thomas (K)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.

B Tas (B)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.

C Cooper (C)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.

C A Getty (CA)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.

R van der Waal (R)

Central Acute and Addictions Directorate, South London and Maudsley NHS Foundation Trust, London, SE5 8RS, UK.

M Kelleher (M)

Central Acute and Addictions Directorate, South London and Maudsley NHS Foundation Trust, London, SE5 8RS, UK.

E Finch (E)

Central Acute and Addictions Directorate, South London and Maudsley NHS Foundation Trust, London, SE5 8RS, UK.

P Bijral (P)

Change, Grow, Live Charity, Management Offices, M4 1NA, Manchester, UK.

D Taylor (D)

Central Acute and Addictions Directorate, South London and Maudsley NHS Foundation Trust, London, SE5 8RS, UK.

J Scott (J)

University of Bath, BAA2 7AY, Bath, UK.

J Strang (J)

King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AB, UK.
Central Acute and Addictions Directorate, South London and Maudsley NHS Foundation Trust, London, SE5 8RS, UK.

Classifications MeSH